Medpace/$MEDP
1D1W1MYTD1Y5YMAX
Capital at risk
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
- Ticker
- $MEDP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,500
- Headquarters
- Cincinnati, United States
- Website
- www.medpace.com
Medpace Metrics
BasicAdvanced
$17B
34.66
$17.06
1.15
-
Price and volume
Market cap
$17B
Beta
1.15
52-week high
$677.90
52-week low
$373.00
Average daily volume
244K
Financial strength
Current ratio
0.732
Quick ratio
0.658
Long term debt to equity
27.682
Total debt to equity
33.216
Profitability
EBITDA (TTM)
611.2
Gross margin (TTM)
72.35%
Net profit margin (TTM)
17.67%
Operating margin (TTM)
20.97%
Effective tax rate (TTM)
17.94%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
20.10%
Return on equity (TTM)
162.15%
Valuation
Price to earnings (TTM)
34.664
Price to revenue (TTM)
6.005
Price to book
38.04
Price to tangible book (TTM)
-63.08
Price to free cash flow (TTM)
23.642
Free cash flow yield (TTM)
4.23%
Free cash flow per share (TTM)
25.011
Growth
Revenue change (TTM)
24.67%
Earnings per share change (TTM)
26.75%
3-year revenue growth (CAGR)
18.48%
10-year revenue growth (CAGR)
23.12%
3-year earnings per share growth (CAGR)
26.83%
10-year earnings per share growth (CAGR)
109.83%
What the Analysts think about Medpace
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Analyst projections of the future price of Medpace stock.
Bulls say / Bears say
Medpace posted robust Q2 results, with revenue up 17.2% year-over-year to $707.3 million, beating analyst estimates and reflecting sustained demand for its clinical trial services (Investing.com).
Net new business awards surged 28.2% year-over-year to $795.7 million in Q2, yielding a net book-to-bill ratio of 1.13x and boosting backlog to over $3.0 billion, underpinning forward revenue visibility (Investing.com).
The company raised full-year 2026 guidance, forecasting revenue of $2.805–$2.885 billion and GAAP EPS of $17.25–$17.95, both above consensus, signaling management’s confidence in sustained growth momentum (Investing.com).
Analysts have raised concerns over bookings momentum and revenue visibility despite Q2 strength, prompting at least two analyst downgrades in the past two weeks (Investing.com).
Medpace’s revenue was nearly flat sequentially from $706.6 million in Q1 to $707.3 million in Q2, suggesting potential deceleration in its growth trajectory (Investing.com).
Sector-wide fears of AI-driven disruption have weighed on Medpace’s valuation, as investors speculate that advanced AI tools could enable drugmakers to insource clinical research, potentially reducing demand for CRO services (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Medpace Financial Performance
Revenues and expenses
Medpace Earnings Performance
Company profitability
Upcoming events
No upcoming events
Medpace News
AllArticlesVideos
Funds containing Medpace
AllUSDEURGBP
Fund name | Fund size | $MEDP weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.52% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.52% |
iShares Healthcare Innovation£DRDR | £1B | 1.52% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.14% |
iShares Nasdaq US Biotechnology£BTEK | £867M | 1.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.